Drug intelligence / Profile preview

MK-6837 + pembrolizumab

Development stage: Unknown
Lead developer: Merck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MK-6837 + pembrolizumab is an investigational combination therapy for advanced or metastatic solid tumors that have not responded to standard treatments. Pembrolizumab is a monoclonal antibody checkpoint inhibitor targeting PD-1, enhancing T-cell–mediated antitumor immunity. The mechanism and precise molecular target(s) of MK-6837 have not been publicly disclosed. The combination aims to augment antitumor immune responses beyond pembrolizumab alone and is currently being evaluated in a Phase 1 trial for safety, pharmacokinetics, and preliminary efficacy, with both agents administered via intravenous infusion every three weeks[1][2][5][7][8].

Other names: MK-6837 + KEYTRUDAMK-6837 + MK-3475

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on MK-6837 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-6837 + pembrolizumab.

Explore the full profile